TcLand Expression will receive 1.2 million Euros from Oseo and ERDF to support a leading project in personalised medicine focused on Rheumatoid Arthritis

The biotech company TcLand Expression is pleased to announce the financial support awarded by Oseo and the European Regional Development Fund (ERDF) for the validation study of the first companion diagnostic test in rheumatoid arthritis. The program is mainly dedicated to setting up a prospective European multicentre clinical trial to validate the diagnostic performance of a molecular test to predict non-response to anti-TNF treatment (in particular infliximab Remicade®) in Rheumatoid Arthritis patients. EN.

La société TcLand Expression est heureuse d’annoncer le financement, par Oséo et le Fond Européen de Développement Régional (FEDER), de son programme de validation des performances cliniques du premier diagnostic compagnon dans la polyarthrite rhumatoïde. Le support d’Oséo, avec l’appui du FEDER, porte essentiellement sur la réalisation d’un essai prospectif multicentrique européen de validation des performances cliniques du test RA-INF-Dx. Ce test est un outil d’aide à l’identification de patients souffrant de polyarthrite rhumatoïde et susceptibles de ne pas répondre à un traitement par un anti-TNF : l’infliximab (Remicade ®). FR.

Posted in Business / Finance | Comments Off

TcLand Expression’s board of directors appoints highly qualified personalized medicine expert Felix Frueh PhD, as new board member

TcLand Expression, a leading company focused on gene expression biomarkers in immunology and personalized medicine today announced the appointment of Felix Frueh PhD, as new member of the company’s Board of Directors. EN.

TcLand Expression SA, société leader dans le domaine des biomarqueurs d’expression de gènes en immunologie et médecine personnalisée annonce aujourd’hui la nomination du Dr. Felix Frueh, en tant que nouveau membre de son conseil d’administration. FR.

Posted in Corporate | Comments Off

TcLand Expression is part of the Innovative Medicines Initiative “Be The CURE”, the largest European consortium for Rheumatology

TcLand Expression, a leading company focused on gene expression biomarkers in immunology and personalized medicine, today is pleased to announce its participation in the Innovative Medicines Initiative (IMI) project “Be The CURE”.EN.

TcLand Expression est heureux d’annoncer sa participation au projet “Be The Cure”, sélectionné dans le cadre du second appel à projet de l’IMI (Innovative Medicines Initiative).FR.

Posted in R&D / Quality | Comments Off

TcLand Expression launches the “PRINT” international clinical trial to validate its blood biomarker RA-INF-Dx and announces the recruitment of its first patient

TcLand Expression launches the “PRINT” international clinical trial to
validate its blood biomarker RA-INF-Dx and announces the recruitment of
its first patient

TcLand Expression annonce la mise en place de « PRINT », étude clinique
internationale de validation de son marqueur sanguin RA-INF-Dx et le premier patient recruté

Posted in R&D / Quality | Comments Off

TcLand Expression nominated as a featured member of the US Personalized Medicine Coalition

TcLand Expression nominated as a featured member of the US Personalized Medicine Coalition

TcLand Expression distinguée comme membre emblématique de la “Personalized Medicine Coalition”

Posted in Uncategorized | Comments Off

Scientific and Medical Advisory Board dedicated to Rheumatology

Posted in R&D / Quality | Comments Off

Peter Payne appointed as Chief Business Officer and Head of US Operations

TcLand Expression strengthens its senior management team by appointing Peter Payne as Chief Business Officer and Head of US Operations.

TcLand Expression renforce son équipe dirigeante senior avec la nomination de Peter Payne en tant que Directeur du Business Développement (CBO) et responsable des opérations Nord Américaines

Posted in Corporate | Comments Off

First EPEMED conference

EPEMED, European personalized medicine Association organized its first conference in Paris. FR.

Posted in Corporate | Comments Off

Licensing agreement with Inserm Transfert

TcLand Expression signs a licensing agreement with Inserm Transfert and initiates a strategic collaboration on the development of companion diagnostic tests for rheumatoid arthritis therapies. EN. FR.

Posted in Business / Finance | Comments Off

Major new partnership with research institute

TcLand Expression initiates major partnership with the Hospital Vall d’Hebron Research Institute and gets exclusive rights on key intellectual property in the field of novel biomarkers in rheumatoid arthritis. EN. FR.

Posted in R&D / Quality | Comments Off